These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 29809161

  • 1. Cost Effectiveness of Becaplermin Gel on Wound Closure for the Treatment of Pressure Injuries.
    Gilligan AM, Waycaster CR, Milne CT.
    Wounds; 2018 Jun; 30(6):197-204. PubMed ID: 29809161
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers.
    Gilligan AM, Waycaster CR, Motley TA.
    Wound Repair Regen; 2015 Jun; 23(3):353-60. PubMed ID: 25810233
    [Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data.
    Persson U, Willis M, Odegaard K, Apelqvist J.
    Value Health; 2000 Jun; 3 Suppl 1():39-46. PubMed ID: 16464208
    [Abstract] [Full Text] [Related]

  • 4. Cost-Effectiveness of Becaplermin Gel on Diabetic Foot Ulcer HealingChanges in Wound Surface Area.
    Waycaster CR, Gilligan AM, Motley TA.
    J Am Podiatr Med Assoc; 2016 Jul; 106(4):273-82. PubMed ID: 27049838
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic benefit of enzymatic debridement of pressure ulcers compared to autolytic debridement with a hydrogel dressing.
    Waycaster C, Milne CT.
    J Med Econ; 2013 Jul; 16(7):976-86. PubMed ID: 23701261
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of adding clostridial collagenase ointment to selective debridement in individuals with stage IV pressure ulcers.
    Carter MJ, Gilligan AM, Waycaster CR, Schaum K, Fife CE.
    J Med Econ; 2017 Mar; 20(3):253-265. PubMed ID: 27774840
    [Abstract] [Full Text] [Related]

  • 7. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O, Persson U, Willis M, Odegaard K.
    Pharmacoeconomics; 2001 Mar; 19(7):767-78. PubMed ID: 11548912
    [Abstract] [Full Text] [Related]

  • 8. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
    Rees RS, Robson MC, Smiell JM, Perry BH.
    Wound Repair Regen; 1999 Mar; 7(3):141-7. PubMed ID: 10417749
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ, Smiell JM, Su Y.
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [Abstract] [Full Text] [Related]

  • 11. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A, Agnew P, Parish L, Joseph R, Galiano RD.
    J Am Podiatr Med Assoc; 2010 May; 100(3):155-60. PubMed ID: 20479444
    [Abstract] [Full Text] [Related]

  • 12. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-utility of a biofilm-disrupting gel versus standard of care in chronic wounds: a Markov microsimulation model based on a randomised controlled trial.
    Carter MJ, Myntti MF.
    J Wound Care; 2019 Jul 01; 28(Sup7):S24-S38. PubMed ID: 31295074
    [Abstract] [Full Text] [Related]

  • 15. Topical becaplermin gel is an effective adjuvant for long-standing ulcers of livedoid vasculopathy recalcitrant to anticoagulant therapy.
    Mushtaq S, Singh S, Mudugal R.
    Clin Exp Dermatol; 2019 Aug 01; 44(6):681-683. PubMed ID: 30706539
    [No Abstract] [Full Text] [Related]

  • 16. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
    Wieman TJ.
    Am J Surg; 1998 Aug 01; 176(2A Suppl):74S-79S. PubMed ID: 9777976
    [Abstract] [Full Text] [Related]

  • 17. Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging; 2008 Aug 01; 3(2):233-40. PubMed ID: 18686746
    [Abstract] [Full Text] [Related]

  • 18. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix.
    Romanelli M, Gilligan AM, Waycaster CR, Dini V.
    Clinicoecon Outcomes Res; 2016 Aug 01; 8():153-61. PubMed ID: 27217787
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of clostridial collagenase ointment on wound closure in patients with diabetic foot ulcers: economic analysis of results from a multicenter, randomized, open-label trial.
    Motley TA, Gilligan AM, Lange DL, Waycaster CR, Dickerson JE.
    J Foot Ankle Res; 2015 Aug 01; 8():7. PubMed ID: 25767565
    [Abstract] [Full Text] [Related]

  • 20. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr 01; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.